Posted on LifeSiteNews.com - May 26, 2021

A city-wide initiative in Mexico’s bustling capital to prescribe ivermectin to COVID-19 positive patients has resulted in a 52–76 percent reduction in hospitalizations, according to research by the Mexican Digital Agency for Public Innovation (DAPI), Mexico’s Ministry of Health, and the Mexican Social Security Institute (IMSS).

Concerned about hospital capacity in the summer of 2020, the Mexican government devised an aggressive testing regime, ramping up from 3,000 tests per day in June to around 24,000 antigen tests every day by that November, according to TrialSiteNews. Mexico City Ministry of Health head Oliva López later announced that doctors will give ivermectin and azithromycin to treat COVID-19.

“The Ministry of Health has identified that there is enough evidence to use in people positive for SARS-CoV-2, even without symptoms, some drugs such as ivermectin and azithromycin,” López confirmed in a press conference.

Local authorities created a home-treatment-kit, including ivermectin, for its 22 million-strong population on December 28, 2020, following a spike in cases of COVID-19.

Individuals testing positive for COVID from an antigen test, and who were experiencing at least mild symptoms, began receiving one of the government’s ivermectin-based treatment kits from December 29.

As part of the program of testing and early treatment, the Mexican government opened a study to track the effect that early treatment of COVID with ivermectin was having on the city’s population. Run by the Mexico Ministry of Health, DAPI, and IMSS, a phone-based monitoring program traced the health of individuals testing positive for COVID with an antigen test. The study followed two cohorts — those who received ivermectin and those who did not — and included 200,000 people, TrialSiteNews revealed.

Using the data garnered from its phone-call-based monitoring system and hospital data on admissions for COVID-19, the researchers discovered a significant reduction in hospitalizations for the group administered ivermectin versus the group which was not, totaling between 52 percent and 76 percent effective at preventing hospitalization.

Dr. Juan J. Chamie-Quintero, a senior data analyst at private Colombian university EAFIT, followed the trends in hospitalizations and deaths in Mexico City before and after the government implemented its ivermectin treatment program.

Chamie-Quintero’s findings corroborated the Mexican government’s observations. The charts below, posted to Chamie-Quintero’s Twitter page, show COVID hospitalizations and deaths both peaking around the middle of January 2021, about two weeks after ivermectin started being distributed on December 29 . . .

[SNIP]